Literature DB >> 1970038

Vigabatrin and behaviour disturbance.

H A Ring, E H Reynolds.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 1970038     DOI： 10.1016/0140-6736(90)91030-e

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  10 in total

Review 1.  A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

Review 2.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

Review 3.  Newer anticonvulsants: comparative review of drug interactions and adverse effects.

Authors:  A Sabers; L Gram
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

Review 5.  Neuropsychiatric complications of epilepsy.

Authors:  Andres M Kanner; Susan Palac
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 6.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 7.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

8.  Effects of vigabatrin on partial seizures and cognitive function.

Authors:  R A Grünewald; P J Thompson; R Corcoran; Z Corden; G D Jackson; J S Duncan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

Review 9.  Newer antiepileptic drugs. Towards an improved risk-benefit ratio.

Authors:  P N Patsalos; J W Sander
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 10.  Behavioural effects of the new anticonvulsants.

Authors:  F M Besag
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.